CWP
GILD icon

Clark Wealth Partners’s Gilead Sciences GILD Stock Holding History

Clark Wealth Partners’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.9K Sell
110
-6
-5% -$791 0.01% 201
2026
Q1 		$16.2K Buy
116
+4
+4% +$560 0.01% 209
2025
Q4 		$13.7K Hold
112
– – 0.01% 218
2025
Q3 		$13.7K Hold
112
– – 0.01% 218
2025
Q2 		$12.4K Sell
112
-4
-3% -$426 0.01% 192
2025
Q1 		$13K Sell
116
-18
-13% -$1.86K 0.01% 178
2024
Q4 		$12.4K Buy
+134
New +$12.1K 0.01% 155

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Clark Wealth Partners's GILD Position: Q2 2026 in Review

Clark Wealth Partners reduced its Gilead Sciences (GILD) stake by 5.2% in Q2 2026, selling an estimated $791 and leaving 110 shares worth $13.9K. The position accounts for 0.01% of the portfolio, ranked #201.

Clark Wealth Partners first reported a position in GILD in Q4 2024 and has held it in 7 quarters since. The position peaked at $16.2K in Q1 2026. 2,169 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Clark Wealth Partners held 110 shares of Gilead Sciences worth $13.9K as of Q2 2026.
  • Clark Wealth Partners sold 6 Gilead Sciences shares in Q2 2026, an estimated $791.
  • Gilead Sciences made up 0.01% of Clark Wealth Partners's portfolio in Q2 2026, its #201 holding.
  • Clark Wealth Partners first reported a position in Gilead Sciences in Q4 2024 and has held it in 7 quarters since.
  • Clark Wealth Partners's Gilead Sciences position peaked at $16.2K in Q1 2026.
  • 2,169 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Clark Wealth Partners's 13F filing for Q2 2026, filed 28 Jul 2026.